User-Fee Sticker Shock? Industry Pursues Trimmed-Down MDUFA IV Proposal
This article was originally published in The Gray Sheet
Device industry groups significantly pared down their review-process reform proposals for the next user-fee program at a meeting with FDA last month. To lower the price tag, they expunged more than a dozen ideas that have been raised by companies or the agency at prior meetings. But FDA sees a lot of important priorities missing in industry's latest five-point plan.
You may also be interested in...
Shuren In The Lion’s Den: Device Center Chief Defends LDT Plan At Clinical Lab Meeting, Fields Wide Array Of Questions
FDA device center Director Jeff Shuren explained and defended fine points of FDA’s proposed laboratory-developed test framework before some of his sharpest critics: members of the American Clinical Laboratory Association, who face an entirely new regulatory scheme once the LDT proposal is finalized.
The agency and industry agreed to create working groups allowing subject-matter experts to delve deeper into technical details on some of the key proposals raised thus far in user-fee reauthorization talks. Areas of focus include de novo reviews, pre-submissions and personnel recruitment challenges.
As the number of de novo applications and pre-submission consultations keep growing, FDA is proposing to institute provide new funding for these programs, among a range of additional proposals laid out in a recent closed-door negotiation. The agency's plan aligns somewhat with an industry proposal, according to meeting minutes, but there is also a lot to negotiate.